Experiment 478772
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | IV |
| Organism | Chelidonium majus (PAPAVERACEAE) |
| Citation | MUSIANOWYCZ,J: JUDMAJER,F: NANFREDA,D: SPANGLER,P: ALBRECHT,H: HOFFMANN,J: MEIJER,D:. (1992). CLINICAL STUDIES OF UKRAIN IN TERMINAL CANCER PATIENTS (PHASE II).. 18() |
| Amount utilized | |
| Compound isolated | |
| Disease | IN THIS PHASE 2 STUDY, 70 PATIENTS WITH A VARIETY OF CANCERS WERE USED. DOSES RANGED FROM 2.5-25 MG PER INJECTION WITH DURATION OF COURSE OF THERAPY BETWEEN 10 AND 90 DAYS. PATIENTS TREATED WITH NO OTHER ADJUVANT THERAPY DEMONSTRATED AMELIORATION OF CLINICAL STATUS IN 26 OF 26 PATIENTS (PARTIAL TUMOR REGRESSION, PAIN REDUCTION OR IMPROVED GENERAL CONDITION). |
| Dose amount | VAR |
| Number | 2 |
| Qualitative result | . |
| Animal | HUMAN ADULT |
| Dose expression | DOSE |